The Use of Plasma-Derived Concentrates

Pier Mannuccio Mannucci, Massimo Franchini

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Von Willebrand disease (VWD) is the most common hereditary bleeding disorder that affects both males and females. It arises from quantitative or qualitative defects of von Willebrand factor (VWF) and causes mucous membrane and soft-tissue bleeding. The aim of treatment is to correct the dual defect of hemostasis caused by the abnormal/reduced VWF and the concomitant secondary deficiency of factor VIII (FVIII). Desmopressin (DDAVP) is the treatment of choice for patients with type 1 VWD who have FVIII and VWF levels of 10 IU/dL or more, while plasma-derived VWF concentrates, either containing FVIII or devoid of this moiety, are indicated for those who are unresponsive or insufficiently responsive to DDAVP (severe type 1, type 2, and type 3 VWD).

Original languageEnglish
Title of host publicationVon Willebrand Disease: Basic and Clinical Aspects
PublisherWiley-Blackwell
Pages200-206
Number of pages7
ISBN (Print)9781405195126
DOIs
Publication statusPublished - Mar 21 2011

    Fingerprint

Keywords

  • Bleeding
  • Factor VIII
  • Therapy
  • Thrombosis
  • Von Willebrand disease
  • Von Willebrand factor
  • VWF/FVIII concentrates

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mannucci, P. M., & Franchini, M. (2011). The Use of Plasma-Derived Concentrates. In Von Willebrand Disease: Basic and Clinical Aspects (pp. 200-206). Wiley-Blackwell. https://doi.org/10.1002/9781444329926.ch17